Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Nervous Tissue: Myelin01:25

Nervous Tissue: Myelin

7.0K
The myelin sheath is a multilayered lipid and protein covering that insulates the axon of a neuron, enhancing the speed of nerve impulse conduction. Axons without this sheath are referred to as unmyelinated. Two types of neuroglia, Schwann cells in the peripheral nervous system (PNS) and oligodendrocytes in the central nervous system (CNS) are responsible for producing myelin sheaths.
Schwann cells begin to form myelin sheaths around axons during fetal development. They wrap around a small...
7.0K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Gait disorders patients with patients with cerebral microangiopathy: association with the microstructural integrity of the tracts involved in walking].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025
Same author

[Comparison of methods for assessing the severity of multiple sclerosis based on a sample of patients from the Moscow region].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025
Same author

[Molecular mechanisms of acute disseminated encephalomyelitis].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025
Same author

[Results of a 5-year project for the early diagnosis of multiple sclerosis in first-line blood relatives (RADIRS program)].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025
Same author

[Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple sclerosis)].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025
Same author

[Quantitative analysis of cerebrospinal fluid flow in multiple sclerosis patients].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025

Related Experiment Video

Updated: Mar 8, 2026

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.3K

[Primary-progressive multiple sclerosis as an atypical demyelinating process].

E V Popova1, V V Bryukhov2, A N Boyko1

  • 1Interregional Department of Multiple Sclerosis at Moscow Clinical Hospital #24, Moscow, Russia; Pirogov Russian National Research Medical University, Moscow, Russia.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|February 1, 2017
PubMed
Summary
This summary is machine-generated.

This article reviews primary-progressive multiple sclerosis (PPMS), comparing its features to other MS forms. It covers diagnostic markers, criteria, and current/future therapeutic strategies for PPMS.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

27.9K

Related Experiment Videos

Last Updated: Mar 8, 2026

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.3K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

27.9K

Area of Science:

  • Neurology
  • Neuroimmunology
  • Clinical Medicine

Background:

  • Multiple Sclerosis (MS) encompasses various clinical subtypes, with primary-progressive MS (PPMS) presenting distinct pathological and clinical features.
  • Understanding PPMS is crucial due to its continuous neurological decline and limited treatment options compared to relapsing forms of MS.

Purpose of the Study:

  • To provide a comprehensive overview of current data on primary-progressive multiple sclerosis (PPMS).
  • To compare PPMS characteristics with other forms of MS.
  • To discuss diagnostic markers, criteria, and therapeutic strategies for PPMS.

Main Methods:

  • Literature review of existing data on primary-progressive multiple sclerosis.
  • Comparative analysis of PPMS against other multiple sclerosis phenotypes.
  • Synthesis of information on diagnostic criteria and therapeutic advancements.

Main Results:

  • PPMS is characterized by gradual neurological deterioration from disease onset, differentiating it from relapsing-remitting MS.
  • Current research is identifying potential biomarkers for earlier and more accurate PPMS diagnosis.
  • Therapeutic options for PPMS remain limited but are an active area of research and development.

Conclusions:

  • Primary-progressive multiple sclerosis requires distinct diagnostic and therapeutic approaches.
  • Further research into disease mechanisms and novel treatments is essential for improving outcomes in PPMS patients.
  • A comprehensive understanding of PPMS characteristics is vital for effective clinical management and future therapeutic development.